Checkpoint blockade-induced autoimmunity: Lessons from mouse models of type 1 diabetes

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Postdoctoral Fellow, Laboratory of Dr. Philip Greenberg, Fred Hutchinson Cancer Research Center, Scholar of the Parker Institute for Cancer Immunotherapy
    BIOGRAPHY

Abstract

Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like symptoms or overt autoimmunity characterized by autoantibody production.  PD-1 inhibition accelerates autoimmunity in mice, but its role in regulating germinal centers is controversial. To address the role of PD-1 in the germinal center reaction in autoimmune type 1 diabetes, we used tetramers to phenotype insulin-specific CD4+ T and B cells in diabetes-prone non-obese diabetic (NOD) mice and diabetes-resistant B6.IAg7 mice. While insulin-reactive lymphocytes were detected in both strains at baseline, they were only antigen-experienced in NOD mice. PD-1 or PD-L1 deficiency, or PD-1  blockade, further unleashed insulin-specific T follicular helper CD4+ T cells and enhanced their survival in NOD mice. This was concomitant with an increase in germinal center B cells and augmented insulin autoantibody production. The effect of PD-1 blockade on germinal centers was reduced when mice were treated with a monoclonal antibody targeting the insulin peptide:MHCII complex. In B6.IAg7 mice, PD-1 blockade did not have any effect, and mice remained autoantibody- and diabetes-free. This work provides an explanation for autoimmune side effects following PD-1 pathway inhibition, and suggests that the state of CD4+ T cell differentiation predetermines its response to PD-1 blockade. Additionally, our work suggests that targeting the self-peptide:MHCII complex may limit autoimmunity arising from checkpoint blockade.

Learning Objectives:

1. Explain the clinical benefits and challenges associated with checkpoint blockade

2. Describe the role of programmed death-1 in mouse models of diabetes

3. Identify ongoing efforts to develop reliable markers for safe and effective use of checkpoint blockade


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
DEC 09, 2021 6:00 AM PST
C.E. CREDITS
DEC 09, 2021 6:00 AM PST
Date: December 9, 2021 Time: 6:00am (PDT), 9:00 am (EDT) As the number of biotherapeutic candidates in development is increasing, the requirements of analytical tools to understand the molec...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
Loading Comments...
Show Resources